Nefopam-d3 (hydrochloride)

Nefopam-d3 (hydrochloride)

• CAS Number: 1346603-30-2
• UNSPSC Description: Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].
• Target Antigen: β-catenin
• Type: Isotope-Labeled Compounds
• Related Pathways: Stem Cell/Wnt
• Applications: Neuroscience-Neuromodulation
• Field of Research: Neurological Disease
• Purity: 98.0
• Solubility: 10 mM in DMSO
• Smiles: [2H]C(N1CCOC(C2=CC=CC=C2)C3=CC=CC=C3C1)([2H])[2H].[H]Cl
• Molecular Weight: 292.82
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11.|[3]Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7(5):e37940.|[4]Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported